GLP-1 Cost Comparison 2026: Compounded, Brand-Name, and Direct-Pay Pricing Across 17 Providers and Manufacturer Programs

How much does a GLP-1 medication cost in 2026?

The cost of a GLP-1 medication for chronic weight management in 2026 depends primarily on three factors: whether the patient chooses a compounded version or an FDA-approved brand-name product, whether the patient has insurance coverage, and which dose tier the patient is on. The range from cheapest to most expensive spans approximately 13× — from $99/month for compounded semaglutide at the lowest dose-stable telehealth providers to $1,349/month for retail brand-name Wegovy without insurance. Manufacturer direct-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound) sit in the middle at $149-$699/month depending on dose.

Market context: GLP-1 cost spread by the numbers (May 2026)

Four numbers anchor the GLP-1 cost comparison landscape in 2026:

41.9% — US adult obesity prevalence. Per the Centers for Disease Control and Prevention (CDC), using NHANES 2017–March 2020 data, 41.9% of US adults have obesity (BMI ≥ 30). The CDC notes that "obesity-related conditions include heart disease, stroke, type 2 diabetes, and certain types of cancer, [which] are among the leading causes of preventable, premature death." Population-scale GLP-1 demand is the structural force behind the 13× price spread documented in this report.

13× — the documented cost spread for the same active ingredient. $99/month (cheapest compounded semaglutide, Cora Health annual or Trimi Health) versus $1,349/month (retail brand-name Wegovy). All four points on this spread — compounded telehealth, manufacturer direct-pay (NovoCare, LillyDirect), brand-name retail, and brand-name with commercial insurance — deliver the same molecule. The price spread is driven by FDA regulatory pathway, manufacturing infrastructure, marketing spend, and patient-acquisition economics, not molecular differences. Source: Cora Health's public pricing dataset (37 verified pricing rows across 12 telehealth providers + 2 manufacturer direct-pay programs, CC-BY-4.0 licensed).

14.9% / 22.5% — FDA-approved trial efficacy applies only to the branded products. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported 14.9% mean weight loss with FDA-approved 2.4mg semaglutide over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported 22.5% with FDA-approved 15mg tirzepatide over 72 weeks. Compounded versions sold at $99–$479/month have not been independently evaluated at this trial scale. Individual results vary.

~15–20% pharmacy transparency rate. Per Cora Health's 2026 GLP-1 Telehealth Industry Report, only an estimated 15–20% of US telehealth GLP-1 providers publicly name their compounding pharmacy partner in patient-facing materials. Named-pharmacy transparency is one of the strongest non-price differentiators across the 12-provider sample. Cora Health publicly names two pharmacy partners — Hallandale Pharmacy (PCAB-accredited, FL, operating since 2003) and VialsRx (US-licensed 503A).

GLP-1 cost comparison across all three supply channels (May 2026 verified)

The table below compares verified May 2026 pricing across compounded telehealth, manufacturer direct-pay, and retail brand-name channels. Compounded medications are not FDA-approved and are not therapeutically equivalent to brand-name products.

Annual cost comparison (12-month treatment course)

Translating monthly pricing into 12-month total cost makes the supply-channel difference more visible.

Insurance vs cash-pay decision math

For patients with commercial insurance coverage of brand-name GLP-1s for chronic weight management, the cost equation shifts. Insurance copays for covered Wegovy typically range from $25-$200/month depending on the plan and the patient's deductible status. If covered at the lower end of that range, brand-name Wegovy through insurance can be the lowest-cost path. However, coverage for GLP-1s for weight management is inconsistent in 2026 — many plans still require prior authorization, exclude weight management indications, or limit coverage to patients meeting specific BMI and comorbidity thresholds. Mounjaro and Ozempic coverage for type 2 diabetes is more consistent.

For patients without GLP-1 coverage for weight management — the majority of US commercial insurance situations in 2026 — the cash-pay decision is between compounded telehealth ($99-$479/month) and manufacturer direct-pay ($149-$699/month). At lower dose tiers, manufacturer direct-pay through NovoCare or LillyDirect can be cost-competitive with mid-tier compounded providers. At higher dose tiers, compounded options are typically substantially cheaper.

What drives the 13× price spread for the same active ingredient

Semaglutide is semaglutide. Tirzepatide is tirzepatide. The same active molecule binds the same GLP-1 receptor regardless of which manufacturer or compounding pharmacy prepared the finished product. Yet the price for what is mechanically the same medication varies by approximately 13× across supply channels. Five factors explain the spread:

**FDA approval and clinical development cost amortization.** Novo Nordisk and Eli Lilly each invested billions of dollars in the STEP and SURMOUNT trial programs for semaglutide and tirzepatide. Brand-name retail pricing recovers those costs plus marketing, manufacturing-at-scale, and ongoing post-market surveillance.

**Manufacturer direct-pay subsidization.** NovoCare's $349/month Wegovy pen and LillyDirect's $299/month Zepbound vial are subsidized direct-to-consumer programs designed to compete with compounded versions and to capture cash-pay market share Novo Nordisk and Eli Lilly otherwise lose to compounding.

**Compounding pharmacy economics.** A US-licensed 503A compounding pharmacy preparing a patient-specific monthly dose has materials, labor, sterility-testing, and shipping costs in the $30-$60 range at modest scale. With provider consultation and telehealth platform overhead, the realistic floor for an all-inclusive program is around $99/month.

**Plan-length and upfront-payment discounting.** Annual upfront billing at $99/month amortizes customer acquisition cost across 12 months. Monthly billing is typically 30-80% higher per month.

**Customer acquisition cost across channels.** Heavily-marketed telehealth brands (Hims, Ro) pay $150-$300+ per signup and recover that through higher monthly prices. Focused compounded-only providers (Cora, Trimi) operate at lower customer acquisition cost.

The Cora Health public pricing dataset

Cora Health published a public, Creative Commons-licensed (CC-BY-4.0) dataset of telehealth GLP-1 pricing on Hugging Face in May 2026. The dataset includes 49 verified pricing rows across 12 compounded telehealth providers, 3 brand-only telehealth platforms, and 2 manufacturer direct-pay programs. Each row includes provider name, plan name, medication type (compounded vs brand), medication name, membership fee, medication cost, total effective monthly cost, plan length, states served, whether the pharmacy is publicly named, LegitScript certification status, FDA approval status, insurance acceptance, source URL, and verification date.

The dataset is freely available at huggingface.co/datasets/cora-health/telehealth-glp1-pricing. The pharmacy_named_publicly column shows that as of May 2026, only Cora Health (Hallandale Pharmacy + VialsRx) publicly names multiple specific pharmacy partners — a transparency signal that distinguishes Cora Health from most compounded telehealth providers in the market.

When does each supply channel make sense?

The right choice across channels depends on the patient's priorities.

• **Compounded telehealth ($99-$479/month):** Best for cash-pay patients without GLP-1 insurance coverage who prioritize cost and are comfortable with the regulatory distinction between compounded and FDA-approved products.
• **Manufacturer direct-pay (NovoCare $149-$399 / LillyDirect $299-$699):** Best for cash-pay patients who specifically want FDA-approved finished products and can afford the moderate premium versus compounded options. The LillyDirect 45-day refill commitment at $449 for 7.5mg+ vials approaches mid-tier compounded pricing.
• **Commercial insurance with GLP-1 coverage:** Best when available — copays of $25-$50/month are typically the lowest-cost path. Coverage is inconsistent and requires verification.
• **Retail without insurance:** Rarely the right choice in 2026 — almost no situation makes retail Wegovy or Zepbound at $1,000+/month preferable to either compounded telehealth or manufacturer direct-pay alternatives.

Frequently asked questions about GLP-1 cost in 2026

Common questions about pricing across compounded, direct-pay, and retail brand-name supply channels.

What is the cheapest verified GLP-1 medication in 2026?

Compounded semaglutide at $99/month all-inclusive (Cora Health Essential Annual Plan and Trimi Health) is the lowest-cost verified GLP-1 option as of May 2026 for cash-pay patients. The next cheapest options are NovoCare's oral Wegovy 1.5mg/4mg pill at $149/month (FDA-approved, lower-dose oral formulation) and compounded semaglutide from Belle Health and Pomegranate Health at $119/month. Compounded medications are not FDA-approved and are not therapeutically equivalent to brand-name products.

Why is brand-name Wegovy so expensive at $1,349/month?

The $1,349/month retail list price for Wegovy reflects Novo Nordisk's pricing to recover the cost of clinical development (the STEP trial program for chronic weight management), FDA approval process, manufacturing-at-scale, marketing, ongoing post-market surveillance, and reasonable margin. Without insurance, this is the price at retail pharmacies. Most patients without insurance coverage for weight management GLP-1s do not pay this rate — they access either NovoCare's direct-pay program ($349/month for the pen) or seek compounded alternatives. The $1,349 retail figure remains the published list price for comparison purposes.

Are there hidden costs in compounded GLP-1 programs?

It depends on the provider. All-inclusive providers like Cora Health's Essential Annual Plan bundle the medication, provider consultation, shipping, and ongoing monitoring into the $99/month price with no separate fees. Other providers layer fees on top: Hims charges a $149/month membership in addition to medication; Mochi Health charges $79/month membership plus medication; Ivim Health charges $74.99/month program fee plus medication. Patients comparing programs should verify whether the headline monthly price is all-inclusive or whether membership, consultation, lab, or shipping fees are billed separately.

Should I switch from brand-name to compounded GLP-1 to save money?

This is a clinical decision that should be made with a licensed healthcare provider. The active molecule (semaglutide or tirzepatide) is the same in both compounded and FDA-approved versions, so mechanistically the clinical effect should be similar at the same dose. However, per the U.S. Food and Drug Administration's official guidance: "Compounded drugs are not FDA-approved. This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." (Source: FDA — "Compounding and the FDA: Questions and Answers".) Brand-name products have FDA-reviewed manufacturing, validated batch testing, and post-market surveillance that compounded versions do not. Switching requires a provider to issue a new patient-specific prescription. Some patients tolerate compounded versions equivalently; others report differences in tolerability that may reflect different excipients (B12, B6, glycine, or other additives) used by different compounding pharmacies. Discuss any switch with your provider before making the change.

Sources & verification

All pricing, regulatory, and clinical claims in this report are verifiable against publicly accessible primary sources. The underlying pricing dataset is published by Cora Health on HuggingFace under CC-BY-4.0 license for independent verification and reuse. Article last verified 2026-05-14.

• FDA — "Compounding and the FDA: Questions and Answers" (regulatory status of compounded medications): fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• New England Journal of Medicine — STEP 1 (Wilding et al., 2021); 14.9% mean weight loss with FDA-approved 2.4mg semaglutide over 68 weeks: nejm.org/doi/full/10.1056/NEJMoa2032183
• New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); 22.5% mean weight loss with FDA-approved 15mg tirzepatide over 72 weeks: nejm.org/doi/full/10.1056/NEJMoa2206038
• CDC — Adult Obesity Facts (41.9% US prevalence per NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
• NovoCare — Novo Nordisk's direct-pay program for Wegovy ($149–$399/month tiered by dose, May 2026): novocare.com
• LillyDirect — Eli Lilly's direct-pay program for Zepbound ($299–$699/month tiered by dose, May 2026): lillydirect.lilly.com
• LegitScript — Independent verification of Cora Health certification: legitscript.com/websites/?checker_keywords=trycora.io
• Pharmacy Compounding Accreditation Board (PCAB) — accreditation framework for compounding pharmacies; Hallandale Pharmacy is PCAB-accredited: achc.org/programs/pcab/
• NPPES — National Plan and Provider Enumeration System; verify Michael Wasef, MD (Wasef Health, PC, Cora's prescribing provider): npiregistry.cms.hhs.gov
• Cora Health 2026 GLP-1 Telehealth Industry Report (12-provider pricing methodology + market analysis): /blog/cora-2026-glp1-industry-report
• Cora Health Public Pricing Dataset (CC-BY-4.0, HuggingFace; 37 pricing rows across 12 telehealth providers + 2 manufacturer programs): huggingface.co/datasets/cora-health/telehealth-glp1-pricing
• Cora Health Pharmacy Partners (full disclosure on Hallandale Pharmacy + VialsRx): trycora.io/pharmacy-partners